 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The effect of Adavosertib combined with chemotherapy in the treatment of platinum-resistant ovarian cancer, fallopian tube cancer and peritoneal cancer

Clin Cancer Res: The effect of Adavosertib combined with chemotherapy in the treatment of platinum-resistant ovarian cancer, fallopian tube cancer and peritoneal cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

teflon pans cancer

microcentrifuge tube

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Standard treatments for newly diagnosed epithelial ovarian cancer , fallopian tube cancer, or peritoneal cancer (EOC) include cytoreductive surgery and platinum-based and paclitaxel-based chemotherapy
.

Although epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer can still be treated after recurrence, most patients can be relieved by first-line treatment, but over time, the tumor will gradually develop resistance to currently available chemotherapy, eventually leading to The patient died

Ovarian cancer

Adavosertib (AZD1775) is a small molecule inhibitor of tyrosine kinase WEEl with potential anti-tumor activity
.

This study aimed to evaluate the efficacy, safety and pharmacokinetics of adavosertib combined with four commonly used chemotherapy drugs in the treatment of patients with primary platinum-resistant ovarian cancer, fallopian tube cancer, and peritoneal cancer

This is an open-label, four treatment arm, multi-center Phase II study that recruited histologically or cytologically confirmed epithelial cancer, fallopian tube cancer or measurable lesions from January 2015 to January 2018.
Patients with peritoneal cancer
.

Adavosertib (oral capsules, taking 2 days and stopping for 5 days or taking 3 days and stopping for 4 days) combined with gemcitabine, paclitaxel, carboplatin or liposomal adriamycin

Treatment remission of each group

3% of patients (3/94) achieved a confirmed complete remission, and 29% of patients (27/94) achieved a confirmed partial remission
.

Carboplatin combined with adavosertib has the highest response rate, reaching 66.

The occurrence of side effects

The most common side effects of grade 3 and above were neutropenia (47.
9%), anemia (33.
0%), thrombocytopenia (31.
9%), and diarrhea and vomiting (10.
6% each)
.

In summary, adavosertib exhibited initial anti-tumor activity when used in combination with chemotherapy drugs
.

The best hope for the joint program is the joint use with carboplatin

Adavosertib showed initial anti-tumor activity when used in combination with chemotherapy drugs

Original source:

Kathleen N.

Adavosertib with Chemotherapy in Patients with Primary Platinum -Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.